1	A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance
2	
3	Lori Bourassa ^{a*} , Garrett A. Perchetti ^{a*} , Quynh Phung ^a , Michelle J. Lin ^a , Margaret G. Mills ^a ,
4	Pavitra Roychoudhury ^{a,b} , Kimberly G. Harmon ^c , Jonathan C. Reed ^a , Alexander L. Greninger ^{a,b#}
5	
6	^a Department of Laboratory Medicine and Pathology, University of Washington, Seattle,
7	Washington, USA
8	^b Viral and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
9	^c Department of Family Medicine, for Stanley Herring Department of Physical Medicine and
10	Rehabilitation, University of Washington, Seattle, Washington, USA
11	
12	*Contributed Equally
13	
14	[#] Corresponding Author, agrening@uw.edu
15	
16	Keywords: SARS-CoV-2, antigen, Sofia 2, Quidel, false negative, variant, nucleocapsid
17	
18	
19	

20 Abstract

21 More than one year into a global pandemic, SARS-CoV-2 is now defined by a variety of rapidly 22 evolving variant lineages. Several FDA authorized molecular diagnostic tests have been 23 impacted by viral variation, while no reports of viral variation affecting antigen test performance 24 have occurred to date. While determining the analytical sensitivity of the Quidel Sofia SARS 25 Antigen FIA test (Sofia 2), we uncovered a high viral load specimen that 26 repeatedly tested negative by this antigen test. Whole genome sequencing of the specimen 27 uncovered two mutations, T205I and D399N, present in the nucleocapsid protein of the 28 isolate. All six SARS-CoV-2 positive clinical specimens available in our laboratory with a D399N 29 nucleocapsid mutation and $C_T < 31$ were not detected by the Sofia 2 but detected by the 30 Abbott BinaxNOW COVID-19 Ag Card, while clinical specimens with the T205I mutation were 31 detected by both assays. Testing of recombinant SARS-CoV-2 nucleocapsid with these variants 32 demonstrated an approximate 1000-fold loss in sensitivity for the Quidel Sofia SARS Antigen 33 FIA test associated with the D399N mutation, while the BinaxNOW and Quidel Quickvue SARS 34 Antigen tests were unaffected by the mutation. The D399N nucleocapsid mutation has been 35 relatively uncommon to date, appearing in only 0.02% of genomes worldwide at time of 36 writing. Our results demonstrate how routine pathogen genomics can be integrated into the 37 clinical microbiology laboratory to investigate diagnostic edge cases, as well as the importance 38 of profiling antigenic diversity outside of the spike protein for SARS-CoV-2 diagnostics. 39

40

41 Introduction

The second year of the SARS-CoV-2 pandemic has been marked by the emergence of a variety of lineages of the virus, several of which are associated with increased transmissibility and immune escape. These variants are generally marked by mutations in the spike protein, which undergoes the most rapid evolution in the coronaviruses due the continual need to escape humoral immunity (1–4). The effect of viral evolution has affected every aspect of the pandemic, from concerns over increased mortality to changes in therapeutic and vaccine efficacy and diagnostic assay performance (5, 6).

49 To date, the FDA has noted four molecular tests whose performance could be altered by 50 SARS-CoV-2 evolution (7). Most famously, S gene target failures in the Thermo TagPath assay 51 mark an N-terminal domain deletion in the spike protein that helps define the B.1.1.7 lineage 52 currently increasing in prevalence across the United States (8). Unlike molecular testing, the 53 effect of SARS-CoV-2 variants on antigen testing is not well understood. No variant affecting 54 antigen test performance has been described to date. Most SARS-CoV-2 antigen tests target 55 the nucleocapsid protein since it is stably associated with the RNA in the virion and present at 56 higher copy number than other viral structural proteins such as spike (9). Most evolutionary 57 analyses in coronavirus have focused on spike protein, since it is responsible for receptor 58 binding and entry and thus a constant target of neutralizing antibodies (4, 10). However, with 59 more than 18 months of spread in humans, a number of coding changes have been found in the 60 nucleocapsid protein (11). Here, we describe the characterization of an uncommon 61 nucleocapsid variant that affects the performance of the Quidel Sofia SARS Antigen FIA antigen 62 test run on the Sofia 2 platform.

63

64 Materials and Methods

65 Specimens and study design

Deidentified, residual patient nasopharyngeal (NP) samples submitted to the University of
Washington Virology Laboratory, Seattle, WA for clinical diagnostic testing were used in this
study. To minimize potential impact of different viral transport media on assay performance, only
clinical samples collected in phosphate-buffered saline (PBS) were used for analytical sensitivity
determination. This study was approved by the University of Washington Institutional Review
Board.

72

73 Quidel Sofia 2 analytical sensitivity determination and confirmation

74 To determine the limit of detection, we created a pooled positive specimen by equally mixing

three residual nasopharyngeal (NP) samples collected in PBS with C_Ts of 23.7, 16.8 and 17.6

by a CDC-based laboratory developed test (12, 13). The pooled specimen was quantified using

two methodologies: reverse transcription-droplet digital PCR (RT-ddPCR, Bio-Rad, Hercules,

78 CA, USA) and qRT-PCR with the SARS-CoV-2 assay on the cobas 6800 (Roche, Basel,

79 Switzerland) as previously described (14).

80

81 Serial 10-fold dilutions of the neat pooled positive sample were run in triplicate on the Sofia 2 82 antigen test. 50µL of each dilution was applied to sterile swabs provided with the Sofia 2 kit 83 to simulate sample collection from the nares (15). The Quidel Reagent Solution was added to a 84 reagent tube and the nasal swab was mixed with the kit reagents by rolling the swab several 85 times and pressing the swab against the bottom of the tube as recommended by the 86 manufacturer. After incubating for 1 minute at room temperature, approximately 120µL of the 87 sample was pipetted into the test cassette. Each cassette was allowed to develop for 15 88 minutes and was read using the Sofia 2 instrument.

89

In addition to the pooled specimen, 58 deidentified residual NP samples collected in PBS that previously tested positive for SARS-CoV-2 on the Roche cobas 6800 with a E-gene C_T range

92 14.27-37.97 were tested on the Sofia 2 SARS Antigen FIA following the methods described

- 93 above.
- 94
- 95 Clinical specimen testing on Abbott BinaxNOW
- 96 Testing of clinical specimens with the Abbott BinaxNOW COVID-19 Ag Card was performed as
- 97 described previously (15). Briefly, swabs provided with the kit were spiked with 50µL of clinical
- 98 nasal specimens previously collected into 3mL of PBS (16). The spiked swab specimen was
- 99 tested following the manufacturer's instructions.
- 100

101 Quantitative RT-PCR and viral load determination of clinical specimens

102 Viral load was determined by testing on the Roche cobas 6800 using the Seracare AccuPlex

103 SARS-CoV-2 Verification Panel standards. SARS-CoV-2 E-gene calibrators of 1e3 (C_T 33.41),

104 1e4 (C_T 30.71), and 1e5 copies (C_T 27.43) were used to calculate -0.33 slope and 14.17

105 intercept from the Roche cobas 6800 platform. Copies per swab were calculated by dividing the

106 copies/mL by 20, based on the 50µL of sample liquid used for rapid test.

107

108 Whole genome sequencing and genome mining

109 SARS-CoV-2 whole genome sequencing was performed using the Swift Biosciences v2 or

110 Illumina COVID-Seq amplicon tiling platforms as described previously (17). To determine

descriptive epidemiology of the nucleocapsid D399N mutation, SARS-CoV-2 whole genomes

- were downloaded from GISAID on April 18, 2021 (18). Figures were generated with custom R
- 113 code (github.com/greninger-lab/sars_cov2_antigen_test_n_gene), using ggplot (18), UpSetR
- 114 (19), and PANGO lineages (20).
- 115

116 Cloning of SARS-CoV-2 N gene wild-type and mutants

117 The ORF encoding N wild-type was amplified from a plasmid encoding N sequence based on 118 NC_045512.2 (a gift from Michael Gale Jr lab) using the COVID-N-C-Strep-F and COVID-N-C-119 Strep-R primers. To obtain the ORF encoding N T205I/D399N, RNA was extracted from a 120 previously sequenced clinical SARS-CoV-2 isolate that encodes the T205I/D399N mutations in 121 N (WA-UW-62718; EPI ISL 1366195) and converted to cDNA using Superscript IV 122 (ThermoFisher Scientific, Waltham, MA, USA)) with COVID-N-C-Strep-R primer followed by 123 PCR utilizing the same primer pair that amplified N wild-type gene. The N wild-type or N 124 T205I/D399N amplicons were then cloned into a modified pcDNA4/TO vector with a C-terminal 125 2x Strep-Tag II using the In-Fusion HD cloning kit (Takara Bio, Kusatsu, Shiga, Japan). To 126 obtain the construct encoding the N T205I amino acid change an amplicon encoding the first 127 half of the N gene encoding T205I (made by PCR using primers COVID-N-C-Strep-F and 128 COVID N nt864R with the N T205I/D399N cDNA template) and an amplicon encoding the 129 second half of the N wild-type gene (made by PCR using primers COVID N nt864R and COVID-130 N-C-Strep-R with the N wild-type plasmid template), were cloned into the modified pcDNA4/TO 131 vector with a C-terminal 2x Strep-Tag II using the In-Fusion HD cloning kit (Takara). The N 132 D399N construct was made following the same strategy except by combining an amplicon 133 encoding the first half of the N wild-type gene (made by PCR using primers COVID-N-C-Strep-F 134 and COVID N nt864R with the N wild-type plasmid) and an amplicon encoding the second half 135 of the N gene encoding D399N (made by PCR using primers COVID N nt864R and COVID-N-136 C-Strep-R with the N T205I/D399N cDNA template). The sequence of all plasmids was 137 confirmed by Sanger sequencing (Genewiz, Inc.) and all primers are listed in Table S1. All PCR reactions were performed with CloneAmp Hi-Fi PCR premix (Takara). 138

139

140 Cell culture, transfection, and cell lysis

141 293T cells were maintained in Dulbecco's modified Eagle medium (DMEM) high glucose with

142 10% fetal bovine serum (FBS), 10 mM HEPES, penicillin and streptomycin. Cells were

transfected with 1 μ g of plasmid DNA using 3:1 ratio of PEI MAX (Polysciences, Inc.

144 Warringston, PA, USA) in Opti-MEM. Cells were harvested 48 h after transfection by washing

145 cells with PBS (with Ca²⁺ and Mg²⁺) followed by lysis in 1xLSM lysis buffer (20 mM HEPES pH

146 7.9, 14 mM KAc, 1 mM NaCl, 1 mM MgAcetate₂, 0.3% NP40) with 1% protease inhibitor cocktail

147 (Sigma-Aldrich, St. Louis, MO, USA). Cell lysates were clarified by centrifugation at 200xg for 10

148 min at 4°C, followed by a second clarification by centrifugation at 21,100g for 1 min at 4°C.

149 Lysates were then stored at -80°C prior to analysis.

150

151 Confirming SARS-CoV-2 N expression and estimating concentration of SARS-CoV-2 N in

152 lysates

153 Total protein in 293T cell lysates was measured using the Pierce BCA protein assay kit

154 (ThermoFisher) and the samples were normalized to 125 µg/mL in sample buffer. To estimate

the concentration of N in cell lysates a titration of recombinant his-tagged N protein

156 (ThermoFisher) was prepared ranging from 62.5 ng to 250 ng in sample buffer. Lysates

157 (1.25 µg per lane) and the titration of recombinant his-tagged N (ThermoFisher) were run on a

158 4-12% Bis-Tris sodium dodecyl sulfate (SDS)-polyacrylamide gel with

159 morpholinepropanesulfonic acid (MOPS) running buffer (Invitrogen, Carlsbad, CA, USA) under

reducing conditions. The samples were then transferred to a 0.45-µm nitrocellulose membrane

using the XCell Blot II module (Invitrogen). Blotting was performed with 1:500 anti-SARS-CoV-2

162 Nucleocapsid Protein (E8R1L) mouse IgG_{2a} monoclonal antibody (Cell Signaling Technology,

163 Danvers, MA, USA) followed by staining with 1:2,000 IRDye 800CW anti-mouse IgG secondary

antibody (Li-Cor Biosciences, Lincoln, NE, USA). Blots were scanned on Sapphire

165 Biomolecular Imager (Azure Biosystems, Dublin, CA, USA) and quantified using Image Studio

166 Lite version 5.2.5 (Li-Cor).

167

168 To estimate the concentration of N in the lysate, the estimated nanograms of N quantified by 169 western blot was divided by 10 to account for loading volume and then multiplied by dilution 170 factor required to bring the lysates to 0.125 mg/mL (lysates were diluted 22.4-fold, 25.6-fold, 171 21.6-fold, and 28-fold for N WT, N T205I, N D399N, and N T205I/D399N, respectively). This 172 resulted in a concentration of 336.2 ng/µL, 189.7 ng/µL, 403.9 ng/µL, 244.2 ng/µL for N WT, N 173 T205I, N D399N, and N T205I/D399N, respectively. These values were used to calculate pg 174 guantity of N going into the 1:10 dilution for N variant based on absorbing 50 µL diluted lysate 175 for each antigen test.

176

177 Abbott BinaxNOW, Quidel Sofia 2, and Quidel QuickVue testing of cell lysates.

178 Lysates from 293T cells transfected with N wildtype, N T205I, N D399N, N T205I/D399N, or 179 pcDNA4/TO vector were kept frozen at -80°C prior to use in antigen testing. Lysates were 180 thawed and diluted in 1×10^{10} lysis buffer at the indicated ten-fold dilutions (from neat to $1:10^{6}$). 181 Subsequent dilutions tested between 10-fold dilutions were either serially diluted from existing 182 10-fold dilutions or a new 10-fold dilution was made and retested. For each test, 50 µL of 183 sample was transferred to 1.5 mL microcentrifuge tube and the material was absorbed to a kit 184 specific swab. The swab was tested following the manufacturer's instructions. BinaxNOW and 185 Quidel QuickVue SARS Antigen Test results were independently evaluated by two individuals, 186 and specimens were called negative if disagreement, inclusive of the 1:100,000 T205I 187 BinaxNow, 1:100,000 WT QuickVue, 1:100,000 D399N QuickVue specimens.

188

189 **Results**

190 Quidel Sofia SARS Antigen FIA analytical sensitivity is approximately 54,900 copies/mL

191 To determine the analytical sensitivity of the Sofia SARS Antigen FIA on the Sofia 2 analyzer

192 (referred to here as the Sofia 2 test), a stock pooled positive sample was determined to have a

193 viral load of 8.66x10⁶ copies/mL by the Roche cobas SARS-CoV-2 assay and

194 1.10x10⁷ copies/mL by RT-ddPCR. Using ten-fold serial dilutions of the pooled sample tested in 195 triplicate, the initial limit of detection (LoD) was determined to be between 1:10 and 1:100 (Table 196 1). Twenty additional 1:10 dilutions were tested to confirm the LoD. However, only 12/20 (60%) 197 specimens of the 1:10 dilution were detected by the assay. Therefore, 1:9 dilutions were tested, 198 with 20/20 (100%) samples detected. Quantification of the 1:9 dilution by the Roche cobas 6800 199 and RT-ddPCR estimated the Sofia 2 SARS Antigen FIA LoD between 9.62x10⁵ and 200 1.22x10⁶ virus copies/mL, respectively. To account for the lower sample volume used by the 201 rapid antigen test compared to RT-PCR platforms (50 µL compared to 200-500 µL used by 202 commercial RT-PCR platforms) a copies/swab and theoretical C_T calculation for 203 the 50µL volume absorbed on the swab was included to better represent the LoD of the antigen test. The LoD of the Sofia 2 SARS antigen FIA was determined at 4.81 x10⁴ and 6.11x10⁴ virus 204 205 copies/swab by cobas 6800 and RT-ddPCR, respectively, or an approximate theoretical qRT-206 PCR C_{T} of 29. 207 To determine whether this analytical sensitivity was reflected in a broader set of 208 specimens, we performed antigen testing on 58 deidentified residual NP swabs collected for 209 clinical diagnostic testing that comprised a wide range of viral loads (C_T 14.27-37.97). Of the 23 samples included within the LoD established using the pooled specimen, 22/23 (95.7%) were 210 211 detected by rapid testing. Three samples below the LoD (2.25x10⁴, 1.24x10⁴, 4.66x10³) 212 copies/swab) were detected but none beyond 4,660 virus copies/swab (0/30), corresponding to

a theoretical cobas 6800 C_T of 32.9, were detected (Figure 1, Table 2).

214

Clinical specimens with nucleocapsid T205I/D399N mutation repeatedly test negative on Quidel
Sofia 2 antigen test

Although the number of positive detections from blinded SARS-CoV-2 samples within the established LoD was >95%, one sample with a viral load of 213,000 copies/swab – far exceeding the estimated LoD of 48,100-61,100 copies/swab – tested negative on the Quidel

Sofia 2. The sample remained negative upon repeat testing on the platform. This sample was
 re-quantified on a separate molecular platform, the Panther Fusion (Hologic, Marlborough, MA,
 USA), and was confirmed to contain approximately 2x10⁵ virus copies/swab.

223 Because of the concern for variants on determining diagnostic assay performance, we 224 performed SARS-CoV-2 whole genome sequencing on this unexpectedly negative specimen. 225 Whole genome sequencing revealed two coding mutations in the N gene, T205I and 226 D399N. Both mutations are located in areas of the 419 as protein without an available structure, 227 with the T205I in the serine-arginine rich region and the D399N in the far C-terminus (21, 22). Of 228 the 1,144,036 GISAID consensus sequences available as of April 18, 2021, we found 222 229 sequences with the D399N mutation, for a global prevalence of only 0.019%. This mutation is 230 found mostly in the United States (n=125, 56.3% of total D399N variants), and most commonly 231 in the background of the B.1.429 / 20C clade (n=63) (Figure 2A/B). We further analyzed D399N 232 in the context of other N gene mutations (Figure 3). D399N rarely emerges alone as a single 233 variant in the N gene (n=11, 5.0%), and most frequently appears with only T205I (n=78, 35.1%). 234 T205I is a common N gene mutation in global consensus sequences, at 42.9% prevalence, 235 making the co-occurrence of D399N and T205I a relatively rare event at only 0.16% of total 236 T205I mutations.

237 Upon review of specimens previously sequenced in our lab, we found an additional 6 238 specimens that contained the same two nucleocapsid mutations and were available for further 239 testing. While 4/6 samples were within the LoD of the Sofia antigen FIA established here, 0/6 240 samples were detected by the assay. Five of the 6 samples harboring the two N gene mutations 241 were detected on a second antigen test, the Abbott BinaxNOW COVID-19 card. The sixth 242 sample was determined to have a theoretical C_T of 37.6, far exceeding the analytical 243 sensitivity of the Abbott BinaxNOW COVID-19, which was previously determined to be an 244 approximate C_T of 29-30 (15).

245

Ectopically expressed nucleocapsid protein containing the D399N mutation results in a ~1000-fold reduction in analytical sensitivity specifically on the Quidel Sofia SARS Antigen FIA test

249 Testing of available clinical samples showed that the Quidel Sofia 2 antigen test has 250 reduced sensitivity for specimens associated with the N T205I/D399N variant, but not for 251 specimens associated with the N T205I variant. Given that the N D399N mutation rarely 252 emerges alone, no clinical specimens were available for antigen testing to directly address 253 whether D399N mutation is solely responsible for the reduced sensitivity of the Quidel Sofia 2 254 antigen test. To evaluate the role of the D399N mutation alone or in combination with T205I, we 255 transiently expressed N variants in 293T cells and subjected lysates from these 293T cells to 256 antigen testing.

257 The N wildtype gene from Wuhan-Hu-1 (N WT) and N gene variants N T205I, N D399N, 258 and N T205I/D399N were each cloned into a CMV expression vector with a C-terminal 2XStrep-259 Tag II. Each of these constructs and the empty vector were transfected into 293T cells and 260 lysates were harvested 48 h post-transfection. Western blot analysis with anti-N of cell lysates 261 and a commercial recombinant N standard was performed to confirm the expression of all 262 recombinant N proteins and to estimate the amount of N protein produced. Based on the 263 estimated nanograms of N loaded into the western blot, the concentration of N in each lysate 264 was estimated to vary from 190 ng/µL to 404 ng/µL (Figure 4).

Next, we wanted to compare the analytical sensitivity of the Quidel Sofia 2 and the Abbott BinaxNOW antigen test kits for the N variants expressed in 293T cells. We confirmed that lysates from 293T cells transfected with the empty vector, which did not express N, were not detected (Table 4). To compare the N variants, we first diluted the lysates that contained a higher concentration of N protein by 3-fold and then each lysate was subjected to a 10-fold serial dilution beginning at 1:10 and ending at 1:10⁶ to determine the limit of detection for each antigen test. Based on the western blot quantification, the expected pg of N per swab from the

1:10 dilution is 5.6x10⁵ pg, 9.5x10⁵ pg, 6.7x10⁵ pg, 12.2x10⁵ pg for N WT, N T205I, N D399N, 272 273 and N T205I/D399N, respectively. In testing of clinical specimens, as described above, the 274 Abbott BinaxNOW test detected specimens associated with both N T205I and N T205I/D399N 275 variants with similar sensitivity. Likewise, the Abbott BinaxNOW kit detected each of these N variants in 293T lysates with equivalent sensitivity down to the 1:10⁵ dilution (3/3 or 2/3 positive 276 277 tests), corresponding to approximately 95 pg of N205I and 122 pg of N T205I/D399N (Table 4). 278 Furthermore, the Abbott BinaxNOW test detected lysates that contain N with just the single 279 mutation D399N or N WT with sensitivity equivalent to the other N variants. Thus, the Abbott 280 BinaxNOW test appears unaffected by the N variants T205I, D399N, or T205/D399N. 281 In contrast to the Abbott BinaxNOW kit, the Quidel Sofia 2 antigen test exhibited 282 significantly lower sensitivity for clinical specimens associated with N T205I/D399N compared to 283 clinical specimens associated with N T205I. Testing of 293T lysates containing N T205I or N 284 T205I/D399N on the Quidel Sofia 2 antigen test confirmed this finding with the antigen test 285 exhibiting an approximately 1000-fold reduced sensitivity between lysates containing variants N 286 T205I versus N T205I/D399N, based on comparing the final dilution where all tests were 287 positive. This corresponded to a difference of approximately 948 pg N T205I and 1.22×10^6 pg 288 of N T205I/D399N (Table 4). In contrast, Quidel Sofia 2 antigen test has approximately 289 equivalent sensitivity between lysates containing N WT and N T205I since both were 100% 290 detected (3/3) at 1:10⁴ dilution or approximately 560 pg of N WT protein and 948 pg of N T2051 291 protein.

To determine if D399N alone is sufficient for the reduced sensitivity of the Quidel Sofia 2 antigen test, we next tested lysates that contain N D399N mutation alone. In contrast to lysates containing N T205I alone or N WT, the sensitivity of the Quidel Sofia 2 antigen test for lysates containing N D399N mutation alone was reduced by 1000-fold (comparing the last dilution where all tests were positive), similar to lysates containing the N T205I/D399N double mutant.

(Table 4). These findings demonstrate that the N D399N mutation alone was sufficient to reduce
the sensitivity of the Quidel Sofia 2 antigen test significantly by 1000-fold.

We next tested the 293T lysates containing N variants on another point-of-care, rapid, FDA authorized COVID-19 antigen test manufactured by Quidel Corporation, Quidel QuickVue, to determine if the Quidel QuickVue kit sensitivity is affected by the N D399N mutation. The QuickVue test is performed as a dipstick test and does not require a reader like the Sofia 2 test. In contrast to our findings on the Quidel Sofia 2 antigen tests, no significant difference was observed in sensitivity between any of the N variants, indicating that the Quidel QuickVue test is not affected by the D399N mutation (Table 4).

306

307 Discussion

308 Here, we simultaneously determined the analytical sensitivity of the Quidel Sofia SARS 309 Antigen FIA run on the Sofia 2 analyzer and uncovered a nucleocapsid variant that dramatically 310 affects the analytical sensitivity of this antigen test. We found the analytical sensitivity of the 311 Quidel Sofia 2 corresponded to 48,100 – 61,100 copies/swab, which closely matches the 312 analytical sensitivity (40,400 – 80,600 copies/swab) we found for the Abbott BinaxNOW (15). 313 While not absolutely comparable, the relative analytical sensitivities agree with those listed in 314 the package inserts for the Quidel Sofia 2 and Abbott BinaxNOW assays of 113 TCID₅₀ units/mL 315 and 140.6 TCID₅₀ units/mL, respectively. Our limited testing against recombinant proteins hinted 316 at a slightly better analytical sensitivity for the Abbott BinaxNOW and Quickvue assays 317 compared to the Quidel Sofia SARS Antigen FIA. However, this testing was run against 318 comparatively few samples and mainly used to demonstrate the semi-quantitative effects of 319 nucleocapsid mutations on test performance. 320 We further characterized a single amino acid mutation (D399N) that affected the

analytical sensitivity of the Quidel Sofia SARS Antigen FIA by approximately 1000-fold, when
 measured on the Sofia 2. The D399N mutation that affected the Quidel Sofia 2 assay

323 performance seems to be of limited public health importance at this time given the few number 324 of cases it has been detected in. It is also a mystery as to how this amino acid change could 325 affect nucleocapsid function. Of note, no complete SARS-CoV-2 nucleocapsid structures are 326 available, with only the N-terminal RNA-binding region and the C-terminal domain (21, 22). 327 Neither the T205I or D399N mutation recovered in our interrogated specimens occurred in these 328 regions, nor could high-confidence models be created for these regions in HHPred (23). Given 329 that one of these mutations affected diagnostic sensitivity, our data illustrate the comparable 330 lack of understanding of how mutations can affect coronavirus nucleocapsid protein as 331 compared to the spike protein.

332 Compared to molecular testing, antigen test performance is often less well-characterized 333 and the effect of viral variation on assay performance only compounds this issue. Antigen tests 334 are often performed in a distributed manner, away from the availability of comparator platforms 335 to monitor test performance. Antigen tests often make use of the entire specimen, obviating the 336 ability to run same sample comparisons on other platforms. And, while it is relatively easy to 337 understand how viral mutation could affect PCR primer binding – even if they are not routinely 338 publicly available for most FDA authorized platforms – antigen testing is often literally a black 339 box, with no public epitope mapping information or even knowledge of whether such data exists. 340 Increasingly, initiatives from the NIH, CDC, and FDA are trying to systematically examine the 341 effect of variants on diagnostic performance, but it is worth noting that multiple molecular tests 342 have already been found to be affected by variants while the first antigen test affected has not 343 been described until more than a year after authorization (24, 25).

The main limitations of the study include the small number of specimens tested, use of specimens that do not follow the manufacturer's recommended testing protocol, use of unpurified recombinant protein lysates to confirm mutation effects, and limited testing to initial determination of analytical sensitivity using recombinant protein. Nonetheless, we found consistent results between use of clinical specimens and recombinant proteins that bulwarks

our results. The Quidel Sofia SARS Antigen FIA is a sandwich ELISA which involves both a
 capture and detection antibody. At this time, it is not clear whether the D399N mutation alters
 binding by the capture or the detection antibody. Without the antibodies used in these assays, it
 is difficult to determine equilibrium dissociation constants, perform epitope mapping, or measure
 other biochemical properties associated with the test reagents.
 Our data further highlight the increasing returns of widespread genome sequencing in

355 the clinical microbiology community (26, 27). With routine SARS-CoV-2 whole genome 356 sequencing available in our lab, we were rapidly able to determine the coding mutations present 357 in a diagnostic edge case. This mutation could further be probed by examining more specimens 358 for which routine genome sequencing had been performed. All told, the work in the clinical 359 virology described here was completed in under four weeks and the antigen test manufacturer 360 was made aware within four days of our testing of the genotyped clinical specimens. Although 361 this specific story uncovered a variant that affected SARS-CoV-2 antigen testing, the ability of 362 decentralized, widespread, routine whole genome sequencing to uncover the genetic basis of 363 assay performance could equally be applied to almost any diagnostic test in the clinical 364 microbiology lab.

365

366

367 Acknowledgements

The authors thank the staff of UW Virology as well as financial support from the Chisholm Foundation, and Quidel and Abbott for providing in-kind kits for testing. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. ALG reports contract testing from Abbott and research support from Merck and Gilead. The authors also gratefully acknowledge authors from originating laboratories responsible for obtaining the specimens and the submitting laboratories where genetic

- 374 sequence data were generated and shared via the GISAID Initiative, on which some of this
- 375 research is based.
- 376
- 377

378 References

Faria NR, Mellan TA, Whittaker C, Claro IM, Candido D da S, Mishra S, Crispim MAE, Sales 379 1. 380 FCS, Hawryluk I, McCrone JT, Hulswit RJG, Franco LAM, Ramundo MS, de Jesus JG, 381 Andrade PS, Coletti TM, Ferreira GM, Silva CAM, Manuli ER, Pereira RHM, Peixoto PS, 382 Kraemer MUG, Gaburo N, Camilo C da C, Hoeltgebaum H, Souza WM, Rocha EC, de 383 Souza LM, de Pinho MC, Araujo LJT, Malta FSV, de Lima AB, Silva J do P, Zauli DAG, 384 Ferreira AC de S, Schnekenberg RP, Laydon DJ, Walker PGT, Schlüter HM, Dos Santos 385 ALP. Vidal MS. Del Caro VS. Filho RMF. Dos Santos HM. Aguiar RS. Proenca-Modena JL. 386 Nelson B, Hay JA, Monod M, Miscouridou X, Coupland H, Sonabend R, Vollmer M, Gandy 387 A, Prete CA, Nascimento VH, Suchard MA, Bowden TA, Pond SLK, Wu C-H, Ratmann O, 388 Ferguson NM, Dye C, Loman NJ, Lemey P, Rambaut A, Fraiji NA, Carvalho M do PSS, 389 Pybus OG, Flaxman S, Bhatt S, Sabino EC. 2021. Genomics and epidemiology of the P.1 390 SARS-CoV-2 lineage in Manaus, Brazil. Science https://doi.org/10.1126/science.abh2644. 391 2. Tegally H. Wilkinson E. Lessells RJ. Giandhari J. Pillay S. Msomi N. Mlisana K. Bhiman JN. 392 von Gottberg A, Walaza S, Fonseca V, Allam M, Ismail A, Glass AJ, Engelbrecht S, Van Zyl 393 G, Preiser W, Williamson C, Petruccione F, Sigal A, Gazy I, Hardie D, Hsiao N-Y, Martin D, 394 York D, Goedhals D, San EJ, Giovanetti M, Lourenço J, Alcantara LCJ, de Oliveira T. 2021. 395 Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat Med 27:440–446. 396 3. McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G, Duprex 397 WP. 2021. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody 398 escape. Science 371:1139–1142.

Eguia RT, Crawford KHD, Stevens-Ayers T, Kelnhofer-Millevolte L, Greninger AL, Englund
 JA, Boeckh MJ, Bloom JD. 2021. A human coronavirus evolves antigenically to escape
 antibody immunity. PLoS Pathog 17:e1009453.

402	5.	Starr TN, Greaney AJ, Dingens AS, Bloom JD. 2021. Complete map of SARS-CoV-2 RBD
403		mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-
404		CoV016. Cell Rep Med 2:100255.
405	6.	Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Edmunds WJ, Jewell NP, Diaz-
406		Ordaz K, Keogh RH. 2021. Increased mortality in community-tested cases of SARS-CoV-2
407		lineage B.1.1.7. Nature https://doi.org/10.1038/s41586-021-03426-1.
408	7.	Health C for D and R. 2021. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. FDA
409	8.	Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, Mayhew M, Megram O, Ashford
44.0		
410		F, White T, Moles-Garcia E, Crawford L, Bosworth A, Atabani SF, Plant T, McNally A. 2021.
411		S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in
412		samples tested by ThermoFisher TaqPath RT-qPCR. The Journal of Infectious Diseases
413		https://doi.org/10.1093/infdis/jiab082.
414	9.	Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, Zhang J, Weng T, Zhang Z, Wu Z, Cheng L,
415		Shi D, Lu X, Lei J, Crispin M, Shi Y, Li L, Li S. 2020. Molecular Architecture of the SARS-

- 416 CoV-2 Virus. Cell 183:730-738.e13.
- 417 10. Kistler KE, Bedford T. 2021. Evidence for adaptive evolution in the receptor-binding domain
 418 of seasonal coronaviruses OC43 and 229e. eLife 10:e64509.
- 419 11. Troyano-Hernáez P, Reinosa R, Holguín Á. 2021. Evolution of SARS-CoV-2 Envelope,
- 420 Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the
- 421 Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week.
- 422 Viruses 13.

423	12. Nalla AK	Casto AM	, Huang M-LW	', Perchetti GA	, Sampoleo R	, Shrestha L	, Wei Y	, Zhu H	,
-----	--------------	----------	--------------	-----------------	--------------	--------------	---------	---------	---

- 424 Jerome KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection
- 425 Assays using Seven Different Primer/Probe Sets and One Assay Kit. J Clin Microbiol
- 426 https://doi.org/10.1128/JCM.00557-20.
- 427 13. Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL. 2020.
- 428 Comparison of Commercially Available and Laboratory Developed Assays for in vitro
- 429 Detection of SARS-CoV-2 in Clinical Laboratories. J Clin Microbiol
- 430 https://doi.org/10.1128/JCM.00821-20.
- 431 14. Perchetti GA, Nalla AK, Huang M-L, Zhu H, Wei Y, Stensland L, Loprieno MA, Jerome KR,

432 Greninger AL. 2020. Validation of SARS-CoV-2 detection across multiple specimen types. J
433 Clin Virol 128:104438.

434 15. Perchetti GA, Huang M-L, Mills MG, Jerome KR, Greninger AL. 2020. Analytical Sensitivity

435 of the Abbott BinaxNOW COVID-19 Ag CARD. J Clin Microbiol

- 436 https://doi.org/10.1128/JCM.02880-20.
- 437 16. Perchetti GA, Huang M-L, Peddu V, Jerome KR, Greninger AL. 2020. Stability of SARS-
- 438 CoV-2 in Phosphate-Buffered Saline for Molecular Detection. J Clin Microbiol 58.
- 439 17. Addetia A, Lin MJ, Peddu V, Roychoudhury P, Jerome KR, Greninger AL. 2020. Sensitive
- 440 Recovery of Complete SARS-CoV-2 Genomes from Clinical Samples by Use of Swift
- 441 Biosciences' SARS-CoV-2 Multiplex Amplicon Sequencing Panel. J Clin Microbiol 59.
- 442 18. Shu Y, McCauley J. 2017. GISAID: Global initiative on sharing all influenza data from
 443 vision to reality. Euro Surveill 22.
- 19. Wickham H. 2016. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York.

- 20. Conway JR, Lex A, Gehlenborg N. 2017. UpSetR: an R package for the visualization of
 intersecting sets and their properties. Bioinformatics 33:2938–2940.
- 447 21. Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X, He S, Zhou Z, Zhou Z, Chen Q, Yan
- 448 Y, Zhang C, Shan H, Chen S. 2020. Crystal structure of SARS-CoV-2 nucleocapsid protein
- 449 RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B
- 450 10:1228–1238.
- 451 22. Yang M, He S, Chen X, Huang Z, Zhou Z, Zhou Z, Chen Q, Chen S, Kang S. 2020.
- 452 Structural Insight Into the SARS-CoV-2 Nucleocapsid Protein C-Terminal Domain Reveals a
- 453 Novel Recognition Mechanism for Viral Transcriptional Regulatory Sequences. Front Chem
- 454 8:624765.
- 455 23. Söding J, Biegert A, Lupas AN. 2005. The HHpred interactive server for protein homology
 456 detection and structure prediction. Nucleic Acids Res 33:W244-248.
- 457 24. Casto AM, Huang M-LW, Xie H, Jerome KR, Wald A, Johnston CM, Greninger AL. 2020.
- 458 Herpes Simplex Virus Mistyping due to HSV-1 × HSV-2 Interspecies Recombination in Viral
- 459 Gene Encoding Glycoprotein B. Viruses 12.
- 460 25. Greninger AL. 2019. Societal Implications of the Internet of Pathogens. J Clin Microbiol 57.
- 461

462

463 Figure Legends:

Figure 1. Confirmation of analytical sensitivity of the using clinical specimens. Specimens are depicted in descending order by copies/swab from left to right. Specimens depicted with purple circles were detected by the Quidel Sofia 2 while gold circles were undetected. The analytical sensitivity determined using dilutions of a pooled positive of 54,900 copies/swab is denoted by the dotted line. The arrow denotes the specimen that was negative on repeat testing and subjected to whole genome sequencing.

470

471 **Figure 2.** Prevalence of D399N mutations in deposited GISAID consensus sequences. A)

472 Distribution of deposited GISAID genomes with the D399N mutation across the globe. Each dot

473 represents sequences in a GISAID-defined subregion, with area of the dot proportional to the

474 number of sequences. Dots are colored by PANGO lineage. B) Distribution of deposited GISAID

genomes with the D399N mutation over time. Countries and subregions are indicated on the

476 left. Each dot represents a unique deposited sequence, colored by PANGO lineage.

477

Figure 3. D399N in the context of other N gene mutations in deposited GISAID consensus
sequences. Matrix shows co-occurrences of D399N with other N gene mutations, sorted in
descending frequency from left to right, with frequencies plotted above as a bar plot. Frequency
of each individual mutation is plotted to the left. Highlighted in orange are the genomes with
D399N without any co-occurring N gene mutations. N gene mutations with <10 total co-

483 occurrences are collapsed into an "Other N mutations" category.

484

485 **Figure 4.** Western blot quantitation of ectopically expressed recombinant SARS-CoV-2

486 nucleocapsid protein in 293T cells. To evaluate N protein expression, total protein normalized

487 lysates from 293T cells transfected with N Wuhan-Hu-1 (WT), N T205I, N D399N, N

488 T205I/D399M, or empty vector and either 250 ng, 125 ng, or 62.5 ng of recombinant N were

- 489 subjected to SDS-PAGE followed by DN western blot. The estimated nanograms of N loaded
- 490 per lane for each variant is shown beneath the western blot determined from a standard curve
- 491 generated by quantification of the commercial recombinant N standards.

492

493

Tables

Table 1. Analytical sensitivity of Quidel SARS Antigen FIA test using dilution of a pooled positive

Sample Dilution	Initial Replicates Detected	Initial % Positive	Confirmator y Replicates Detected	Copies/m L (ddPCR)	Copies/swab (ddPCR)	Copies/mL (Cobas 6800)	Copies/swa b (Cobas 6800)
Neat	3/3	100%		1.10E+07	5.50E+05	8.66E+06	1.73E+05
1:9	3/3	100%	20/20	1.22E+06	6.11E+04	9.62E+05	4.81E+04
1:10	3/3	100%	12/20	1.10E+06	5.50E+04	8.66E+05	4.33E+04
1:20	0/3	0%		5.50E+05	2.75E+04	4.33E+05	8.66E+03
1:30	0/3	0%		3.67E+05	1.83E+04	2.89E+05	5.77E+03
1:40	0/3	0%		2.75E+05	1.38E+04	2.16E+05	4.33E+03
1:50	0/3	0%		2.20E+05	1.10E+04	1.73E+05	3.46E+03
1:100	0/3	0%		1.10E+05	5.50E+03	8.66E+04	1.73E+03
1:1,000	0/3	0%		1.10E+04	5.50E+02	8.66E+03	4.81E+01
1:10,000	0/3	0%		1.10E+03	5.50E+01	8.66E+02	4.33E+01
1:100,000	0/3	0%		1.10E+02	5.50E+00	8.66E+01	8.66E+00
Pos Control	6/6	100%					
Neg Control	0/6	0%					

Table 2. Confirmation of Analytical Sensitivity of Quidel SARS Antigen FIA test on Sofia 2 analyzer using clinical specimens. Clinical specimens in PBS transport media were spiked onto swabs for antigen test, resulting in a calculated theoretical C_T value of how much virus was used as input for the antigen test.

UW Sample ID	Original Roche cobas C _⊺	Original Copies / mL	Copies / swab	Theoretical Roche cobas C _T	Quidel SOFIA 2 Antigen Detection
PBS 21	14.24	2.67E+09	1.34E+08	19.6	Positive
PBS 10	14.49	2.20E+09	1.10E+08	19.9	Positive
PBS 2	15.12	1.36E+09	6.80E+07	20.5	Positive
PBS 7	17.23	2.69E+08	1.35E+07	22.6	Positive
PBS 33	17.41	2.34E+08	1.17E+07	22.8	Positive
PBS 35	19.18	6.02E+07	3.01E+06	24.5	Positive
PBS 32	19.19	5.98E+07	2.99E+06	24.5	Positive
PBS 29	19.35	5.28E+07	2.64E+06	24.7	Positive
PBS 38	19.8	3.74E+07	1.87E+06	25.2	Positive
PBS 55	20.38	2.40E+07	1.20E+06	25.7	Positive
PBS 15	20.5	2.19E+07	1.09E+06	25.8	Positive
PBS 37	20.52	2.15E+07	1.08E+06	25.9	Positive
PBS 53	21.01	1.48E+07	7.39E+05	26.4	Positive
PBS 14	21.29	1.19E+07	5.96E+05	26.6	Positive
PBS 45	21.3	1.18E+07	5.91E+05	26.6	Positive
PBS 19	21.56	9.69E+06	4.84E+05	26.9	Positive
PBS 52	21.58	9.54E+06	4.77E+05	26.9	Positive
PBS 22	21.63	9.18E+06	4.59E+05	27.0	Positive
PBS 26	22.52	4.64E+06	2.32E+05	27.9	Positive
PBS 36	22.63	4.26E+06	2.13E+05	28.0	Negative
PBS 34	22.66	4.16E+06	2.08E+05	28.0	Positive
PBS 51	23.23	2.69E+06	1.34E+05	28.6	Positive
PBS 25	24.22	1.26E+06	6.28E+04	29.6	Positive
PBS 47	24.48	1.03E+06	5.15E+04	29.8	Negative
PBS 27	25.56	4.49E+05	2.25E+04	30.9	Positive
PBS 57	26.33	2.49E+05	1.24E+04	31.7	Negative
PBS 28	26.35	2.45E+05	1.23E+04	31.7	Positive
PBS 9	27.61	9.31E+04	4.66E+03	32.9	Positive
PBS 12	28.13	6.25E+04	3.12E+03	33.5	Negative
PBS 43	28.56	4.49E+04	2.25E+03	33.9	Negative
PBS 23	29.14	2.88E+04	1.44E+03	34.5	Negative
PBS 58	29.15	2.86E+04	1.43E+03	34.5	Negative

PBS 30	29.3	2.54E+04	1.27E+03	34.6	Negative
PBS 50	29.36	2.43E+04	1.22E+03	34.7	Negative
PBS 8	29.61	2.01E+04	1.00E+03	34.9	Negative
PBS 1	30.21	1.27E+04	6.33E+02	35.5	Negative
PBS 11	30.26	1.22E+04	6.09E+02	35.6	Negative
PBS 41	30.53	9.90E+03	4.95E+02	35.8	Negative
PBS 31	30.79	8.11E+03	4.05E+02	36.1	Negative
PBS 3	30.83	7.86E+03	3.93E+02	36.1	Negative
PBS 16	31.43	4.96E+03	2.48E+02	36.7	Negative
PBS 48	31.74	3.91E+03	1.95E+02	37.1	Negative
PBS 18	31.82	3.68E+03	1.84E+02	37.1	Negative
PBS 44	31.87	3.54E+03	1.77E+02	37.2	Negative
PBS 5	32.55	2.10E+03	1.05E+02	37.9	Negative
PBS 46	32.67	1.91E+03	9.57E+01	38.0	Negative
PBS 17	32.79	1.75E+03	8.73E+01	38.1	Negative
PBS 42	33.2	1.27E+03	6.37E+01	38.5	Negative
PBS 54	33.2	1.27E+03	6.37E+01	38.5	Negative
PBS 49	33.58	9.52E+02	4.76E+01	38.9	Negative
PBS 39	33.66	8.95E+02	4.48E+01	39.0	Negative
PBS 40	33.97	7.06E+02	3.53E+01	39.3	Negative
PBS 24	34.02	6.79E+02	3.40E+01	39.3	Negative
PBS 56	34.14	6.19E+02	3.10E+01	39.4	Negative
PBS 13	34.21	5.87E+02	2.93E+01	39.5	Negative
PBS 4	36	1.49E+02	7.43E+00	41.3	Negative
PBS 20	37.73	3.94E+01	1.97E+00	43.0	Negative
PBS 6	37.97	3.27E+01	1.64E+00	43.3	Negative

Specimen	Cobas 6800 C _⊤ (E-gene)	Theoretical Roche cobas C _T	Quidel Sofia 2	Abbott BinaxNOW	Nucleocapsid Mutation	Lineage	GISAID EPI
DM1	32.58	37.9	Negative	Negative	T205I, D399N	B.1.429	EPI_ISL_1209060
DM2	21.85	27.2	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1110097
DM3	25.48	30.8	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1789833
DM4	20.44	25.8	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1069365
DM5	21.72	27.1	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1366181
DM6	23.25	28.6	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1366195
DM7*	22.63	28.0	Negative	n.d.	T205I, D399N	B.1.429	EPI_ISL_1708574
M8	15.29	20.7	Positive	Positive	T205I	B.1.429	EPI_ISL_1405087
M9**	24.27	29.6	Positive	Negative	T205I	B.1.429	EPI_ISL_1405089
M10**	22.3	27.6	Negative	Positive	T205I	B.1.429	EPI_ISL_1405090
M11	21.21	26.6	Positive	Positive	T205I	B.1.429	EPI_ISL_1405112
M12	24.41	29.7	Positive	Positive	T205I	B.1.429	EPI_ISL_1405113
M13	22.47	27.8	Positive	Positive	T205I	B.1.429	EPI_ISL_1405115
M14	24.06	29.4	Positive	Positive	T205I	B.1.429	EPI_ISL_1405119
M15	23.4	28.7	Positive	Positive	T205I	B.1.429	EPI_ISL_1405138
M16	20.06	25.4	Positive	Positive	T205I	B.1.429	EPI_ISL_1405141
M17	22.78	28.1	Positive	Positive	T205I	B.1.429	EPI_ISL_1405148
M18	17.47	22.8	Positive	Positive	T205I	B.1.429	EPI_ISL_1405151

Table 3. Antigen test results for available clinical specimens containing D399N and T205I nucleocapsid mutants

*Original discordant sample

**M9 and M10 were diluted to create enough volume to run on cobas 6800 for a fresh C_T (Dilution was prepared prior to both antigen and molecular testing)

n.d., not done

Table 4. Antigen testing results for detection of transiently expressed nucleocapsid proteins. The approximate initial limit of detection is highlighted in bold, where both highlighted 2/3 decisions involved a split decision on the 3^{rd} specimen in question. The estimated amount of protein placed on a swab was calculated based on the western blot in Figure 4.

Sample	Dilution	Sofia 2	BinaxNOW	QuickVue	Estimated protein (pg)
Negative Control	1:100	0/1	0/1	0/3	
Wild-type N	1:10	3/3		3/3	560400
	1:100	3/3		3/3	56040
	1:1000	3/3	3/3	3/3	5604
	1:10000	3/3	3/3	3/3	560
	1:100000	0/3	3/3	2/3	56
	1:1000000		0/3	0/3	6
N T205I	1:10	3/3	1/1	1/1	948500
	1:100	3/3	1/1	3/3	94850
	1:1000	3/3	3/3	3/3	9485
	1:10000	3/3	3/3	3/3	948
	1:100000	0/3	2/3	3/3	95
	1:1000000		0/3	0/3	9
N D399N	1:10	6/6		3/3	673200
	1:100	1/6		3/3	67320
	1:1000	0/3	3/3	3/3	6732
	1:10000	0/3	3/3	3/3	673
	1:100000	0/3	3/3	2/3	67
	1:1000000		0/3	0/3	7
N T205I/D399N	1:10	4/4	1/1	1/1	1220800
	1:100	2/6	1/1	3/3	122100
	1:1000	0/3	3/3	3/3	12210
	1:10000	0/3	3/3	3/3	1221
	1:100000	0/3	3/3	3/3	122
	1:1000000		0/3	0/3	12



.

Α

											100 million (1997)	
				# Sampl	es•	1 ●	10 🧲	20	30		¥	
	Line	age	 A.2.4 B B.1 B.1.1 B.1.130 	 B.1 B.1 B.1 B.1 B.1 B.1 	.1.37 .1.7 .1.72 .131	 B.1 B.1 B.1 B.1 B.1 	.177.31 .2 .221 .234 243	 B.1.258.1 B.1.351 B.1.36 B.1.397 B.1.429 	12 B.1. B.1. B.1. B.1. B.1.	526 527 530 595		
В			• B.1.1.33	• B.1	.160.30	• B.1	.258	• B.1.474	• 11.0			
Argentina	Santa Fe	•••••								••••••••		
Australia	New South Wales	• • • • •										
Belgium	Velm · Schaarbeek · Neerpelt · Balen ·										•	
Brazil	Rio Grande do Sul											
Ecuador	Imbabura ·	• • • • •										
Germany	Unspecified Thuringia Saxony Hamburg Brandenburg Berlin Baden-Wurttemberg										•	
India	Odisha ·	• • • • • •										
Ireland	Dublin ·											
Japan	Unspecified ·	•										
Kenya	Mombasa											
Luxembourg	Luxembourg ·	•										
Mexico	Zacatecas · Puebla ·										• • • • • • • •	DO
Netherlands	Overijssel ·	•••••										• • • • • • • • • • • •
Panama	San Miguelito	•••••								• • • • • • • • • •		
Poland	Malopolskie ·	• • • • •									• • • • • • • •	
Slovakia	Bratislava ·	• • • • •										
South Africa	Western Cape ·	• • • • •								• • • • • • • •		
Spain	Galicia · Catalunya ·											• • • • • • • • • • • • •
Switzerland	Zurich ·	• • • • •								••••		
UK	Scotland · Great Britain ·							••••	• • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • •
	Wyoming Wisconsin Utah Texas Rhode Island Pennsylvania Oregon New York	•								•••		
USA	Mississippi Michigan Massachusetts Maryland Kentucky Kansas Illinois Georgia Connecticut Colorado California Arizona								•	•) • 0 • 0 • 0
	ALZOIR AS	10-04-01	020-05-01 202	2020-2020	01-0 ¹ 2020	08-0 ¹ 202		10-0 ¹ 2020-11-0 ²	2020-202	1.01.07 2021.07	,0 ¹ ,0 ³ ,0 ¹	102 ¹⁻⁰⁴⁻⁰¹

Collection Date



Sequences with Mutation



ng N: 150.1 74.1 187.0 87.2